Company profile

Sensorion specializes in the research and development of medicines for the treatment of inner ear disorders (dizziness or loss of balance, hearing problems, tinnitus, etc.). At the end of 2018, the company has a portfolio of 2 products in Phase II clinical development (SENS-111 for the treatment of acute attack of vertigo, and SENS-401 for the protective treatment of internal ear tissue in case of lesional attacks).

Source: Cofisem - Last Update: 17 Jul 2020
Key Executives
Chief Executive Officer Nawal Ouzren
VP, Financial Communication Catherine Leveau
Source: Cofisem - Last Update: 22 May 2020
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales
Consumed purchases 177 160 123
Payroll 3,140 2,331 2,618 1,914 1,583
Operating profit -10,814 -12,226 -9,991 -9,107 -5,322
Income tax 1,886 1,662 1,065
Net income -12,096 -12,350 -8,116 -7,412 -4,271
Net consolidated income (Group share) -12,096 -12,350 -8,116 -7,412 -4,271
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 17 Jul 2020
Shareholder information
Invus 12.78 %
Innobio 10.85 %
Sofinnova 6.06 %
Inserm Transfert Initiative 3.05 %
Cochlear 1.66 %
0.69 %
Source: Cofisem - Last Update: 22 May 2020

Financial analysis

Equity research report, in partnership with Morningstar

View Report

Address

Sensorion

375 Rue du Professeur Joseph Blayac
FR-34080 Montpellier
France
Source: Cofisem - Last Update: 17 Jul 2020

Contact

Source: Sensorion - Last Update: 17 Jul 2020